Is GKOS or ESTA more profitable?

Establishment Labs has a net margin of -19.05% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% Establishment Labs -19.05% -218.77% -12.31%

Does the media refer more to GKOS or ESTA?

In the previous week, Glaukos had 2 more articles in the media than Establishment Labs. MarketBeat recorded 8 mentions for Glaukos and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.30 beat Glaukos' score of 1.09 indicating that Establishment Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Establishment Labs 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ESTA or LQDA?

Establishment Labs has higher revenue and earnings than Liquidia. Establishment Labs is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Establishment Labs $211.08M 11.82 -$51.06M -$1.49 N/A Liquidia $158.32M 39.92 -$68.92M $0.14 507.64

Does the media refer more to ESTA or LQDA?

In the previous week, Liquidia had 11 more articles in the media than Establishment Labs. MarketBeat recorded 17 mentions for Liquidia and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.30 beat Liquidia's score of 0.48 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BLCO or ESTA?

In the previous week, Establishment Labs had 5 more articles in the media than Bausch + Lomb. MarketBeat recorded 6 mentions for Establishment Labs and 1 mentions for Bausch + Lomb. Establishment Labs' average media sentiment score of 1.30 beat Bausch + Lomb's score of 0.49 indicating that Establishment Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Establishment Labs 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend STVN or ESTA?

Establishment Labs has a consensus price target of $87.14, indicating a potential upside of 2.75%. Given Establishment Labs' higher probable upside, analysts plainly believe Establishment Labs is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.86 Establishment Labs 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Does the media prefer STVN or ESTA?

In the previous week, Establishment Labs had 2 more articles in the media than Stevanato Group. MarketBeat recorded 6 mentions for Establishment Labs and 4 mentions for Stevanato Group. Establishment Labs' average media sentiment score of 1.30 beat Stevanato Group's score of 0.80 indicating that Establishment Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Establishment Labs 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LIVN or ESTA?

In the previous week, Establishment Labs had 4 more articles in the media than LivaNova. MarketBeat recorded 6 mentions for Establishment Labs and 2 mentions for LivaNova. Establishment Labs' average media sentiment score of 1.30 beat LivaNova's score of 1.21 indicating that Establishment Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Establishment Labs 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Establishment Labs (ESTA) Competitors

$84.81 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$84.71 -0.10 (-0.12%)

As of 06/18/2026 04:17 PM Eastern

Compare

ESTA vs. GKOS, LQDA, BLCO, STVN, and LIVN

Should you buy Establishment Labs stock or one of its competitors? MarketBeat compares Establishment Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Establishment Labs include Glaukos (GKOS), Liquidia (LQDA), Bausch + Lomb (BLCO), Stevanato Group (STVN), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

How does Establishment Labs compare to Glaukos?

Glaukos (NYSE:GKOS) and Establishment Labs (NASDAQ:ESTA) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Glaukos has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

In the previous week, Glaukos had 2 more articles in the media than Establishment Labs. MarketBeat recorded 8 mentions for Glaukos and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.30 beat Glaukos' score of 1.09 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos currently has a consensus target price of $149.17, suggesting a potential upside of 13.98%. Establishment Labs has a consensus target price of $87.14, suggesting a potential upside of 2.75%. Given Glaukos' stronger consensus rating and higher probable upside, equities analysts clearly believe Glaukos is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Establishment Labs has lower revenue, but higher earnings than Glaukos. Establishment Labs is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	15.15	-$187.69M	-$3.28	N/A
Establishment Labs	$211.08M	11.82	-$51.06M	-$1.49	N/A

Establishment Labs has a net margin of -19.05% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Establishment Labs	-19.05%	-218.77%	-12.31%

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 10.0% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Glaukos beats Establishment Labs on 10 of the 16 factors compared between the two stocks.

How does Establishment Labs compare to Liquidia?

Establishment Labs (NASDAQ:ESTA) and Liquidia (NASDAQ:LQDA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Establishment Labs has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Liquidia has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by insiders. Comparatively, 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Liquidia had 11 more articles in the media than Establishment Labs. MarketBeat recorded 17 mentions for Liquidia and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.30 beat Liquidia's score of 0.48 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Establishment Labs has higher revenue and earnings than Liquidia. Establishment Labs is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	11.82	-$51.06M	-$1.49	N/A
Liquidia	$158.32M	39.92	-$68.92M	$0.14	507.64

Establishment Labs presently has a consensus target price of $87.14, suggesting a potential upside of 2.75%. Liquidia has a consensus target price of $60.29, suggesting a potential downside of 15.17%. Given Establishment Labs' higher possible upside, equities research analysts plainly believe Establishment Labs is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Liquidia	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.90

Liquidia has a net margin of 7.74% compared to Establishment Labs' net margin of -19.05%. Liquidia's return on equity of 46.82% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Liquidia	7.74%	46.82%	7.06%

Summary

Liquidia beats Establishment Labs on 10 of the 17 factors compared between the two stocks.

How does Establishment Labs compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and Establishment Labs (NASDAQ:ESTA) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Establishment Labs has lower revenue, but higher earnings than Bausch + Lomb. Establishment Labs is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.21B	1.02	-$360M	-$0.62	N/A
Establishment Labs	$211.08M	11.82	-$51.06M	-$1.49	N/A

In the previous week, Establishment Labs had 5 more articles in the media than Bausch + Lomb. MarketBeat recorded 6 mentions for Establishment Labs and 1 mentions for Bausch + Lomb. Establishment Labs' average media sentiment score of 1.30 beat Bausch + Lomb's score of 0.49 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Establishment Labs	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bausch + Lomb has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Bausch + Lomb presently has a consensus target price of $17.92, indicating a potential upside of 20.33%. Establishment Labs has a consensus target price of $87.14, indicating a potential upside of 2.75%. Given Bausch + Lomb's higher possible upside, analysts clearly believe Bausch + Lomb is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Bausch + Lomb has a net margin of -4.21% compared to Establishment Labs' net margin of -19.05%. Bausch + Lomb's return on equity of 3.60% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Establishment Labs	-19.05%	-218.77%	-12.31%

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by company insiders. Comparatively, 10.0% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Establishment Labs beats Bausch + Lomb on 9 of the 16 factors compared between the two stocks.

How does Establishment Labs compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Establishment Labs (NASDAQ:ESTA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Stevanato Group has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Stevanato Group has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	3.98	€158.21M	€0.59	29.88
Establishment Labs	$211.08M	11.82	-$51.06M	-$1.49	N/A

In the previous week, Establishment Labs had 2 more articles in the media than Stevanato Group. MarketBeat recorded 6 mentions for Establishment Labs and 4 mentions for Stevanato Group. Establishment Labs' average media sentiment score of 1.30 beat Stevanato Group's score of 0.80 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Establishment Labs has a consensus price target of $87.14, indicating a potential upside of 2.75%. Given Establishment Labs' higher probable upside, analysts plainly believe Establishment Labs is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

72.9% of Establishment Labs shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by insiders. Comparatively, 10.0% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Stevanato Group has a net margin of 11.76% compared to Establishment Labs' net margin of -19.05%. Stevanato Group's return on equity of 10.27% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.76%	10.27%	6.08%
Establishment Labs	-19.05%	-218.77%	-12.31%

Summary

Stevanato Group beats Establishment Labs on 9 of the 17 factors compared between the two stocks.

How does Establishment Labs compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Establishment Labs (NASDAQ:ESTA) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

LivaNova has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 10.0% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Establishment Labs has lower revenue, but higher earnings than LivaNova. Establishment Labs is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.11	-$242.47M	$1.95	40.26
Establishment Labs	$211.08M	11.82	-$51.06M	-$1.49	N/A

LivaNova has a net margin of 7.48% compared to Establishment Labs' net margin of -19.05%. LivaNova's return on equity of 16.48% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Establishment Labs	-19.05%	-218.77%	-12.31%

LivaNova currently has a consensus target price of $79.38, indicating a potential upside of 1.11%. Establishment Labs has a consensus target price of $87.14, indicating a potential upside of 2.75%. Given Establishment Labs' higher probable upside, analysts clearly believe Establishment Labs is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Establishment Labs had 4 more articles in the media than LivaNova. MarketBeat recorded 6 mentions for Establishment Labs and 2 mentions for LivaNova. Establishment Labs' average media sentiment score of 1.30 beat LivaNova's score of 1.21 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Establishment Labs beats LivaNova on 8 of the 15 factors compared between the two stocks.

Get Establishment Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESTA vs. The Competition

Export

Metric	Establishment Labs	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.50B	$8.76B	$6.42B	$12.59B
Dividend Yield	N/A	1.73%	2.68%	5.81%
P/E Ratio	-56.92	24.73	24.78	24.44
Price / Sales	11.82	22.64	534.03	118.32
Price / Cash	N/A	102.97	45.07	55.09
Price / Book	104.70	5.64	10.80	6.58
Net Income	-$51.06M	$179.69M	$3.57B	$337.17M
7 Day Performance	3.25%	1.96%	0.72%	0.83%
1 Month Performance	19.07%	2.99%	0.41%	2.25%
1 Year Performance	124.31%	6.36%	29.34%	36.14%

Establishment Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESTA Establishment Labs	1.7081 of 5 stars	$84.81 flat	$87.14 +2.8%	+124.3%	$2.50B	$211.08M	N/A	1,004	News Coverage Positive News Gap Down
GKOS Glaukos	3.668 of 5 stars	$131.10 +0.7%	$148.00 +12.9%	+30.5%	$7.70B	$507.44M	N/A	1,094	News Coverage Positive News Analyst Forecast
LQDA Liquidia	3.1575 of 5 stars	$69.55 -3.1%	$60.29 -13.3%	+439.6%	$6.20B	$158.32M	498.39	50	News Coverage Insider Trade
BLCO Bausch + Lomb	3.4272 of 5 stars	$15.03 +0.2%	$17.92 +19.2%	+27.3%	$5.36B	$5.10B	N/A	13,000	Short Interest Increase
STVN Stevanato Group	2.7172 of 5 stars	€16.51 -0.8%	N/A	-24.6%	€5.03B	€1.34B	28.14	6,010	News Coverage Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESTA) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Establishment Labs (ESTA) Competitors

ESTA vs. GKOS, LQDA, BLCO, STVN, and LIVN

How does Establishment Labs compare to Glaukos?

Summary

How does Establishment Labs compare to Liquidia?

Summary

How does Establishment Labs compare to Bausch + Lomb?

Summary

How does Establishment Labs compare to Stevanato Group?

Summary

How does Establishment Labs compare to LivaNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESTA vs. The Competition

Establishment Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Establishment Labs (ESTA) Competitors

ESTA vs. GKOS, LQDA, BLCO, STVN, and LIVN

How does Establishment Labs compare to Glaukos?

Which has more risk and volatility, GKOS or ESTA?

Does the media refer more to GKOS or ESTA?

Do analysts recommend GKOS or ESTA?

Which has stronger valuation and earnings, GKOS or ESTA?

Is GKOS or ESTA more profitable?

Do institutionals & insiders hold more shares of GKOS or ESTA?

Summary

How does Establishment Labs compare to Liquidia?

Which has more volatility and risk, ESTA or LQDA?

Do institutionals & insiders hold more shares of ESTA or LQDA?

Does the media refer more to ESTA or LQDA?

Which has better valuation and earnings, ESTA or LQDA?

Do analysts prefer ESTA or LQDA?

Is ESTA or LQDA more profitable?

Summary

How does Establishment Labs compare to Bausch + Lomb?

Which has preferable valuation & earnings, BLCO or ESTA?

Does the media prefer BLCO or ESTA?

Which has more volatility and risk, BLCO or ESTA?

Do analysts recommend BLCO or ESTA?

Is BLCO or ESTA more profitable?

Do institutionals and insiders have more ownership in BLCO or ESTA?

Summary

How does Establishment Labs compare to Stevanato Group?

Which has more risk & volatility, STVN or ESTA?

Which has better earnings and valuation, STVN or ESTA?

Does the media prefer STVN or ESTA?

Do analysts recommend STVN or ESTA?

Do insiders and institutionals have more ownership in STVN or ESTA?

Is STVN or ESTA more profitable?

Summary

How does Establishment Labs compare to LivaNova?

Which has more risk and volatility, LIVN or ESTA?

Do insiders & institutionals believe in LIVN or ESTA?

Which has stronger valuation and earnings, LIVN or ESTA?

Is LIVN or ESTA more profitable?

Do analysts prefer LIVN or ESTA?

Does the media refer more to LIVN or ESTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESTA vs. The Competition

Establishment Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools